Literature DB >> 17362671

Mineralocorticoid receptor antagonists.

Hari Krishnan Parthasarathy1, Thomas M MacDonald.   

Abstract

With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of mineralocorticoid receptor antagonists has provided clinicians with an important tool towards complete blockade of the renin-angiotensin-aldosterone axis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17362671     DOI: 10.1007/s11906-007-0009-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   4.592


  43 in total

Review 1.  Aldosterone: cardiovascular assault.

Authors:  Allan D Struthers
Journal:  Am Heart J       Date:  2002-11       Impact factor: 4.749

2.  The general adaptation syndrome and the diseases of adaptation.

Authors:  H SELYE
Journal:  J Clin Endocrinol Metab       Date:  1946-02       Impact factor: 5.958

3.  Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.

Authors:  John M Flack; Suzanne Oparil; J Howard Pratt; Barbara Roniker; Susan Garthwaite; Jay H Kleiman; Yonghong Yang; Scott L Krause; Diane Workman; Elijah Saunders
Journal:  J Am Coll Cardiol       Date:  2003-04-02       Impact factor: 24.094

4.  Tolerance of spironolactone.

Authors:  B R Hughes; W J Cunliffe
Journal:  Br J Dermatol       Date:  1988-05       Impact factor: 9.302

5.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.

Authors:  K Swedberg; P Eneroth; J Kjekshus; L Wilhelmsen
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

6.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

7.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

8.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 9.  Hypokalemia: causes, consequences and correction.

Authors:  R D Lindeman
Journal:  Am J Med Sci       Date:  1976 Jul-Aug       Impact factor: 2.378

10.  Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism.

Authors:  C G Brilla; L S Matsubara; K T Weber
Journal:  J Mol Cell Cardiol       Date:  1993-05       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.